Clinical pharmacokinetics of acamprosate

Clinical Pharmacokinetics

Volumn 35, Issue 5, 1998, Pages 331-345

  Saivin, Sylvie ^a,b   Hulot, Thierry ^c   Chabac, Sylvie ^c   Potgieter, Adrian ^c   Durbin, Philippe ^c   Houin, Georges ^a,b  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Monterre LIPHA SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; DIAZEPAM; DISULFIRAM; IMIPRAMINE; NEUROLEPTIC AGENT;

ALCOHOL WITHDRAWAL; ALCOHOLISM; AREA UNDER THE CURVE; BIOEQUIVALENCE; BODY WEIGHT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENTERIC COATED TABLET; FOOD DRUG INTERACTION; GENDER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STEADY STATE;

EID: 0031743018     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835050-00001     Document Type: Review

References (44)

1. Saivin S, Hulot T, Theodor R, et al. Bioequivalence study for highly variable drugs: the example of acamprosate. Pharm Res. In press
2. Sass H, Potgieter AS, Lehert P. Results from a polled analysis of 11 European trials comparing acamprosate and placebo on the treatment of alcohol dependence. Alcohol Alcohol 1995; 30 (4): 551
3. Paille F, Guelfi JD, Perkins A, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30 (2): 239-47
4. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-42
5. Poldrugo F, Chabac S, Lehert P, et al. Acamprosate in the long-term treatment of alcoholism: is its use recommended within the psycho-social approach? Alcohol Clin Exp Res 1994; 18 (2): 43A
6. Pelc I, Le Bon O, Verbanck P, et al. Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicenter study. In: Novel pharmacological interventions in alcoholism. New York: Springer. 1992
7. Chabenat C, Ladure P, Moore N, et al. Application of an analytical method to calcium acetylhomotaurinate determination. Arzneimittel Forschung 1989; 39 (II): 1413-4
8. Chabenat C, Ladure P, Moore N, et al. Determination of calcium acetylhomotaurinate by liquid chromatography with fluorimetric and electrochemical detection. J Chromatogr 1987; 414 (2): 417-22
9. Girault J, Gobin P, Fourtillan JB. Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr 1990; 530: 295-305
10. Littleton JM. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179-88
11. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. TIPS 1997; 18: 54-9
12. Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. I. Characterisation of spermidine sensitive acamprosate binding site (ABS) in rat brain. Alcohol Clin Exp Res 1998; 22 (4): 802-9
13. Al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate: II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22 (4): 810-4
14. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992; 41 (4): 669-74
15. Nalpas B, Dabadie H, Parot P, et al. L'acamprosate: de la pharmacologie à la clinique. Encephale 1990; 16 (3): 175-9
16. Boismare F, Daoust M, Moore ND, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984; 21 (5): 787-9
17. Le Magnen J, Tran G, Durlach J, et al. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4 (2): 97-102
18. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurinate in animals. Pharmacol Biochem Behav 1989; 32 (3): 607-11
19. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53 (6): 1038-53
20. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22 (3): 573-9
21. Lipha, Campral, prescribing information. Lyon, France, 1995
22. Fourtillan JB. Pharmacokinetics of acetylhomotaurinate (AOTA) in young healthy volunteers subjects after single and multiple oral administrations of doses equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca). Lipha, France, 1990; AD 875 H. (Data on file)
23. Jaillon P, Salvat M. Pharmacokinetics study of intravenous administration of AOTAL (calcium acetylhomotaurinate) at single doses of 10, 20 and 30 mg/kg. Lipha, France, 1991. (Data on file)
24. Dewland PM. A rising dose tolerance and pharmacokinetic study of calcium his acetyl homotaurine following single oral administration of a solution at four dose levels. Lipha, France, 1991. RD 298/17927. (Data on file)
25. Fourtillan JB. Pharmacokinetics and relative bioavailabilities of acetylhomotaurinate (AOTA) after oral administration of a single dose equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca) in six young healthy volunteers, when given as aqueous solution and enteric coated tablets. Lipha, France, 1989; AD 864 H. (Data on file)
26. Fourtillan JB. Influence of food on acetylhomotaurine pharmacokinetics after single oral administration of acamprosate. Lipha, France, 1992; AD 1011 H. (Data on file)
27. Sennesael J. Acaniprosate pharmacokinetic study after a single oral administration of 2 acamprosate tablets (2 × 333 mg) to subjects with normal or impaired renal function. Lipha, France, 1992; AOTA-CIN IRI-AD 1003 H. (Data on file)
28. Dewland PM. Report of an investigation of the effect of ethanol upon the pharmacokinetics of acamprosate. Lipha, France, 1991; RD 298/17949. (Data on file)
29. Dewland PM. Report of the comparison of the plasma pharmacokinetics of acamprosate following a single oral dose to equal numbers of men and women. Lipha, France, 1995; RD 298/20673. (Data on file)
30. Haug G. Pharmacokinetic study of 2 acamprosate tablets (2×333 mg) in patients with different stages of impaired liver function compared to a control group of healthy volunteers. Lipha, France, 1992; 90235. (Data on file)
31. Fourtillan JB. Research of pharmacokinetic interactions between diazepam and acamprosate when given in combination on multiple oral dosing. Lipha, France, 1995; AD 1126 H. (Data on file)
32. Dewland PM. Report of the potential pharmacokinetic interaction of disulfiram with acamprosate. Lipha, France, 1995; RD 298/20828. (Data on file)
33. Pelc I. Acamprosate pharmacokinetic study during the treatment of alcoholic patients following withdrawal. Lipha, France, 1993; AOTA-CIN PAI-AD 1054 H. (Data on file)
34. Miguet J. Plasma kinetics of acamprosate after a single oral administration to patients with liver disease. Lipha, France, 1991; AOTA-CIN IHP I. (Data on file)
35. De Boer AG, Voorwinden H, Durbin P, et al. The influence of Acamprosate on the trans-epithelial-electrical resistance (TEER) and the paracellular transport across caco-2 monolayers [poster]. 6th European Congress of Biopharmaceutics and Pharmacokinetics; 1996 Apr 22-24; Athens
36. Houin G. Preliminary study of in vitro absorption of acamprosate with the everted gut sac method. Lipha, France, 1997; Acamprosate 97.026. (Data on file)
37. Scott G. The metabolism and pharmacokinetics of 14C AOTA-Ca in man. Lipha, France, 1991; IRI 7488. (Data on file)
38. Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral Symposium; 1995 Sep 3; Stuttgart: Springer, 1995: 47-64
39. Lucker PL. A pilot study of the influence of AOTAL on the pharmacokinetics of ethyl alcohol. Lipha, France, 1989; 12/89-03 AL. (Data on file)
40. Klots U, Antonin KH, Bieck PR. Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol 1976; 10: 121-6
41. Kaplan SA, Jack ML, Alexander K, et al. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 1973; 62 (11): 1789-96
42. Fourtillan JB. Research of pharmacokinetic interactions between imipramine and acamprosate when given in combination on multiple oral dosing. Lipha, France, 1995; AD 1135 H. (Data on file)
43. Aubin HJ, Lehert P, Beaupere B, et al. Tolérance de l'association de l'acamprosate aux médicaments du sevrage d'alcool. Essai multicentrique sur 591 alcooliques en sevrage. Alcoologie 1994; 16 (1): 32-41
44. Aubin HJ, Lehert P, Beaupere B, et al. Tolerability of the combination of acamprosate with drugs used to prevent alcohol withdrawal syndrom. Alcoholism 1995; 31 (1-2): 25-38